Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4487088 | 0.83 | MEN1 (0.57) | ATMALDH1A1GAAMAPTKMT2A | |
| SCHEMBL4483934 | 0.82 | MEN1 (0.52) | ATMALDH1A1GAASMN1; SMN2KMT2A | |
| SCHEMBL4482026 | 0.82 | CA12 (0.56) | ATMALDH1A1GAASMN1; SMN2KMT2A | |
| SCHEMBL4483280 | 0.82 | CYP19A1 (0.50) | ATMALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL4479415 | 0.81 | L3MBTL1 (0.52) | POLBALDH1A1GAAMAPTKMT2A | |
| SCHEMBL4473385 | 0.81 | MEN1 (0.50) | ATMALDH1A1GAASMN1; SMN2KMT2A | |
| SCHEMBL4477941 | 0.80 | MEN1 (0.49) | ATMALDH1A1GAAMAPTSMN1; SMN2 | |
| SCHEMBL4489698 | 0.80 | NSD2 (0.49) | POLBALDH1A1GAAMAPTKMT2A | |
| SCHEMBL4483089 | 0.79 | CYP2C19 (0.65) | ALDH1A1GAAMAPTSMN1; SMN2KMT2A | |
| SCHEMBL4483773 | 0.79 | MEN1 (0.60) | ATMALDH1A1GAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598418-B2 | Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-10-06 | — | — | US | claimed |
| US-20050215645-A1 | Amide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2005-09-29 | — | — | US | claimed |
| US-7598418-B2 | Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20050215645-A1 | Amide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215645-A1 | Amide derivatives | OGG1, HDAC1, BCL2A1 | POLB 296/4885ATM 56/4885ALDH1A1 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.